AHMEDABAD: Zydus Lifesciences Limited on Wednesday announced it has received final approval from the United States Food and Drug Administration (USFDA) for two drugs – Venlafaxine extended-release tablets and pregabalin extended-release tablets.
Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It is expected to improve mood and energy levels in patients. The medication is also expected to decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. The pharma major has received a nod for marketing it in 37.5 mg, 75mg, 150mg and 225 mg strengths.
Pregabalin extended release tablets on the other hand are used to treat pain caused by diabetes- or shingles-induced nerve damage and will be marketed in strengths of 82.5 mg, 165 mg and 330 mg.
Pregabalin Extended-Release tablets are used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Both the drugs would be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ-based facility.
Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It is expected to improve mood and energy levels in patients. The medication is also expected to decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. The pharma major has received a nod for marketing it in 37.5 mg, 75mg, 150mg and 225 mg strengths.
Pregabalin extended release tablets on the other hand are used to treat pain caused by diabetes- or shingles-induced nerve damage and will be marketed in strengths of 82.5 mg, 165 mg and 330 mg.
Pregabalin Extended-Release tablets are used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
Both the drugs would be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ-based facility.
